Investigational agent sacituzumab govitecan showed activity in patients with metastatic urothelial cancer, including some previously treated with immune checkpoint inhibitors.
Medscape Medical News
Original Article: Novel Agent Shows Promise in Advanced 'Post-Checkpoint' Bladder Cancer